Andrew Einhorn
2018 - RVL Pharmaceuticals plc
In 2018, Andrew Einhorn earned a total compensation of $505.1K as Chief Financial Officer at RVL Pharmaceuticals plc.
Compensation breakdown
| Non-Equity Incentive Plan | $136,053 |
|---|---|
| Salary | $360,769 |
| Other | $8,250 |
| Total | $505,072 |
Einhorn received $360.8K in salary, accounting for 71% of the total pay in 2018.
Einhorn also received $136.1K in non-equity incentive plan and $8.3K in other compensation.
Rankings
In 2018, Andrew Einhorn's compensation ranked 11,841st out of 14,244 executives tracked by ExecPay. In other words, Einhorn earned more than 16.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,841 out of 14,244 | 17th |
Division Manufacturing | 4,788 out of 5,765 | 17th |
Major group Chemicals And Allied Products | 1,814 out of 2,128 | 15th |
Industry group Drugs | 1,547 out of 1,817 | 15th |
Industry Pharmaceutical Preparations | 1,188 out of 1,391 | 15th |
Source: SEC filing on April 26, 2019.
Einhorn's colleagues
We found three more compensation records of executives who worked with Andrew Einhorn at RVL Pharmaceuticals plc in 2018.